Abbott Laboratories Q3 2026 Earnings Recap

Abbott’s shares were nearly unchanged after the earnings call, up 0.1%. The quarter was accompanied by a plan to separate Nutrition, but the transcript provides limited detail on Q3 performance and frames the separation’s benefits as expected rather than realized.

Key Takeaways

• Abbott intends to spin off its Nutrition business as an independent, publicly traded company; no timing or transaction terms are provided in the excerpt.
• The proposed Nutrition company has approximately $8.5 billion in annual sales, 16,000 employees, and 14 manufacturing sites. Abbott expects it to qualify for S&P 500 inclusion.
• Nutrition’s portfolio includes Similac, PediaSure, Ensure, Glucerna, and Pedialyte. CEO Robert Ford said the market is shifting toward consumer preferences, wellness trends, and retail execution.
• Abbott expects the separation to sharpen focus and says the remaining company’s sales growth should accelerate and margin profile expand; these are forward-looking expectations.
• The excerpt does not include Q3 sales, earnings, or updated financial guidance, limiting assessment of operating performance.